Antimutagenic potency of the cytotoxic and anti-psoriatic compound anthralin (cignolin).
The anti-psoriatic compound anthralin (cignolin) was determined to exhibit a strong cytostatic activity on HeLa-Köln cells; an ED50 concentration of 1.2 microM are cytotoxic for the cells. These growth-inhibition data were confirmed by thymidine-uptake experiments. The drug anthralin was determined to be neither direct a mutagen nor a premutagen in the Ames test using Salmonella typhimurium strain TA 100 (anthralin-concentration = 5 microM). Moreover, this compound was a strong inhibitor of benzo(a)pyrene monooxygenase, an enzyme which causes the metabolic conversion of premutagens to mutagens. These data demonstrate anthralin to be an anti-psoriatic compound devoid of mutagenic property in vitro with regard to base-pair substitutions and provided at least with some antimutagenic potential.
Bernd
A
A
Holzmann
H
H
Marsch
W C
WC
Kurelec
B
B
Britvić
S
S
Müller
W E
WE
D000875:Anthralin / Q000494:pharmacology*; D001579:Benzopyrene Hydroxylase / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D005455:Fluorescent Antibody Technique; D006801:Humans; D007700:Kinetics; D008856:Microscopy, Fluorescence; D009152:Mutagenicity Tests; D009153:Mutagens; D012486:Salmonella typhimurium / Q000235:genetics; D013936:Thymidine / Q000378:metabolism
D009153:Mutagens; D001579:Benzopyrene Hydroxylase; D000875:Anthralin; D013936:Thymidine